Revance Therapeutics (RVNC) Misses Q2 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts RVNC Hot Sheet
Join SI Premium – FREE
Revance Therapeutics (NASDAQ: RVNC) reported Q2 EPS of ($0.88), $0.12 worse than the analyst estimate of ($0.76). Revenue for the quarter came in at $28.4 million versus the consensus estimate of $28.15 million.
For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Bristol Myers Squibb MS CAR T therapy data shows patients off DMTs
- Meta's capital-raising plans expose a major weakness in the AI boom
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
